[1] Angeli P, Gines P, Wong F, et al. Diagnosis and management of acute kindey injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. J Hepatol, 2015,62:968-974.
[2] Fagundes C, Barreto R, Guevara M, et al. A modified acute kidney injury classification for diagnosis and risk stratification of impairment of kidney function in cirrhosis. J Hepatol, 2013,59:474-481.
[3] European Association for the Study of the Liver. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol, 2018,69:406-460.
[4] Chen TK, Knicely DH, Grams ME, et al. Chronic kidney disease diagnosis and management: a review. JAMA, 2019,322:1294-1304.
[5] Francoz C, Nadim MK, Durand F. Kidney biomarkers in cirrhosis. J Hepatol, 2016,65:809-824.
[6] Bassegoda O, Huelin P, Ariza X, et al. Development of chronic kidney disease after acute kindey injury in patients with cirrhosis is common and impairs clinical outcomes. J Hepatol, 2020, 72:1132-1139.
[7] Chawla LS, Eggers PW, Star RA, et al. Acute kidney injury and chronic kidney disease as interconnected syndromes. N Eng J Med, 2014,371:58-66.
[8] Wu CF, Chiang WC, Lai CF, et al. Transforming growth factor beta-1 stimulates profibrotic epithelial signaling to activate pericyte-myofibroblast transition in obstructive kidney fibrosis. Am J Pathol, 2013,182:118-131.
[9] Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the prevention, detection, evaluation and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol, 2018,71:2199-2269.
[10] Brar S, Ye F, James MT, et al. Association of angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use with outcomes after acute kidney injury. JAMA Intern Med, 2018,178:1681-1690. |
